Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer
In a first for the dangling accelerated approvals reviewed by FDA’s oncology adcomm in April, Merck on Thursday afternoon agreed to pull a third-line stomach …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.